The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00090116
- Lead Sponsor
- Forest Laboratories
- Brief Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 400
- Clinical diagnosis of moderate to severe Alzheimer's disease;
- ambulatory patients
- folate deficiency;
- clinically significant central nervous system disease other than Alzheimer's disease;
- clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (34)
Pivotal Research Centers
🇺🇸Peoria, Arizona, United States
21st Century Neurology
🇺🇸Phoenix, Arizona, United States
Margolin Brain Institute
🇺🇸Fresno, California, United States
Pharmacology Research Institute
🇺🇸Northridge, California, United States
UCI Medical Center
🇺🇸Orange, California, United States
Pacific Research Network
🇺🇸San Diego, California, United States
Affiliated Research Institute
🇺🇸San Diego, California, United States
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
Baumel-Eisner Neuromedical Institute
🇺🇸Ft. Lauderdale, Florida, United States
Scroll for more (24 remaining)Pivotal Research Centers🇺🇸Peoria, Arizona, United States